European Medicines Agency Approves Pfizer's 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults

Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) has approved the company’s 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name APEXXNAR. The vaccine is approved for active immunization for the prevention of invasive ...

Related Keywords

Norway ,Italy ,Iceland ,United States ,Liechtenstein ,Lichtenstein ,Nanette Cocero ,Linkedin ,Drug Administration ,Exchange Commission ,Pfizer ,Youtube ,Pfizer Inc ,European Union ,European Medicines Agency ,Facebook ,Committee For Medicinal Products Human Use ,Global President ,Medicinal Products ,Human Use ,Marketing Authorization Application ,Conjugate Vaccine ,Biologics License Application ,Breakthroughs That Change Patient ,Pfizer News ,Annual Report ,Looking Information ,Factors That May Affect Future ,Conjugate Vaccination ,Clin Microbiol ,Deaths Attributable ,Invasive Pneumococcal Disease ,Different Vaccines ,Years Study ,Pneumococcal Vaccines ,Invasive Streptococcus ,Population Based Cohort ,Hum Vaccin ,Valent Pneumococcal Conjugate ,Clin Infect ,Serotypes Recovered ,Hospitalized Adult Patients ,